Realising the potential of synthetic cannabidiol
Our product pipeline currently includes five programs focused on safe and effective topical treatments for serious skin diseases, and leveraging the unique anti-inflammatory, immune-modulating and antimicrobial properties of synthetic cannabidiol.
Botanix also has an exclusive license to use a proprietary drug delivery system PermetrexTM for direct skin delivery of active pharmaceuticals.
Click on a program to view details.
BTX1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers.
Acne is a skin condition that manifests in pimples, lumps and cysts and is the leading cause of visits to dermatologists and is a leading cause of psychological difficulties in adolescents. It is the most common skin disorder in the US affecting 40-50 million Americans and in 2013 was reported to cost more than $2.3 Billion in prescriptions.
Acne has multiple pathogenetic pathways including sebum overproduction, unwanted sebocyte proliferation, inflammation and bacterial infection. The active being studied by Botanix has been shown in scientific studies to:
- normalize excessive lipid synthesis of human sebocytes
- suppress cell proliferation
- provide an anti inflammatory effect
- potentially reduce bacterial infection
Potential benefits of BTX1503:
- BTX1503 could reduce the occurrence or severity of serious acne
- BTX1503 could be a significant alternative to some existing therapies (such as isotretenoin) that are associated with serious side effects, including suicide
BTX1204 is a transdermal gel formation for the treatment of atopic dermititis.
Atopic dermatitis (or severe eczema) is a common inflammatory skin disease most commonly seen in children. An estimated 31.6 million people in the United States have symptoms of eczema or eczematous conditions and at least 17.8 million people have symptoms of atopic dermatitis, considered a more severe form of eczema. Atopic dermatitis is characterized by a loss of barrier function, which is the impermeable outer layer of the skin, and skin inflammation.
The endocannabioid system of the skin has a crucial role skin derived sensory phenomena such as pain and itch. The active being studied by Botanix can exert potent analgesic effects by activation of CB1 and/or CB2 receptors in the skin and possibly other receptors at sensory nerve terminals and/or inflammatory cells
Potential Benefit of BTX 1308:
- PBX 1308 could have a role reducing skin inflammation and improving skin tone
BTX 1702 is a compelling product opportunity for the treatment of papulopustular rosacea. It leverages Botanix Pharmaceutical’s proprietary drug delivery system PermetrexTM with synthetic cannabidiol.
Rosacea is a chronic inflammatory skin disease that often begins with a tendency to blush or flush more easily than other people, but can progress into many subtypes, including papulopustular rosacea. Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face, which affects more than 16 million Americans.
The BTX 1702 program is being expedited based on mechanistic data generated by Botanix that showed synthetic cannabidiol exerts powerful anti-inflammatory and antimicrobial actions in skin – two key activities that are critical to successfully treating rosacea. These studies suggest that synthetic cannabidiol delivered using the PermetrexTM skin delivery technology could represent a safe and effective new option for rosacea patients.
The strong antimicrobial performance of synthetic cannabidiol forms a solid foundation for Botanix Pharmaceutical’s existing skin disease programs, with potential to be a development platform which can be deployed across multiple human and animal health applications.
BTX1308 is a transdermal gel formulation for the treatment of plaque psoriasis.
Psoriasis is a serious medical condition affecting the autoimmune system with about 80% of patients having plaque psoriasis, characterized by raised reddish skin covered with white scales. About 7.5 million Americans have psoriasis and a significant proportion of severe patients cannot be treated with the current standard of care, which is high doses of steroids or monoclonal antibodies.
Psoriasis is an inflammatory disease characterised in part, by epidermal keratinocyte hyper-proliferation. The active being studied by Botanix has been shown to inhibit keratinoctye proliferation in a concentration dependent manner and has anti-inflammatory and anti-bacterial properties
Potential Benefits of BTX1308:
- BTX1308 could reduce the occurrence and severity of psoriasis lesions
- BTX1308 could reduce keratinocyte proliferation, inflammation which along with its anti-bacterial properties may have a synergistic total effect on the disease
Only in the last two decades, has a natural cannabinoid receptor system been discovered in the human body. Identification of the main cannabinoid receptors (CB1 and CB2 ), their endogenous lipid ligands (endocannabinoids), biosynthetic pathways and metabolizing enzymes (collectively termed the endocannabinoid system), coupled with the discovery and/or rational design of numerous ligands for CB receptors, has triggered an exponential growth in studies exploring the continuously growing regulatory functions of this newly discovered physiological system both in health and disease.
Recent scientific research by Botanix and others has confirmed that cannabidiol plays a significant role in normalizing unwanted skin growth, reducing excessive production of oils and reducing inflammation and infection.
The endocannabinoid system has been implicated in the regulation of skin cell proliferation, survival and differentiation, the delicate balance of which is a key determinant of proper skin balance or homeostasis.